BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 8296659)

  • 1. Pooled intravenous immunoglobulin in the management of systemic vasculitis.
    Jayne DR; Lockwood CM
    Adv Exp Med Biol; 1993; 336():469-72. PubMed ID: 8296659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of antineutrophil cytoplasmic autoantibody-positive systemic vasculitis and glomerulonephritis with pooled intravenous gammaglobulin.
    Tuso P; Moudgil A; Hay J; Goodman D; Kamil E; Koyyana R; Jordan SC
    Am J Kidney Dis; 1992 Nov; 20(5):504-8. PubMed ID: 1442764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin.
    Jayne DR; Esnault VL; Lockwood CM
    J Autoimmun; 1993 Apr; 6(2):207-19. PubMed ID: 8499059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin.
    Richter C; Schnabel A; Csernok E; De Groot K; Reinhold-Keller E; Gross WL
    Clin Exp Immunol; 1995 Jul; 101(1):2-7. PubMed ID: 7621588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulin as sole therapy for systemic vasculitis.
    Jayne DR; Lockwood CM
    Br J Rheumatol; 1996 Nov; 35(11):1150-3. PubMed ID: 8948304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.
    Jayne DR; Chapel H; Adu D; Misbah S; O'Donoghue D; Scott D; Lockwood CM
    QJM; 2000 Jul; 93(7):433-9. PubMed ID: 10874052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Wegener's granulomatosis with intravenous immunoglobulin.
    Richter C; Schnabel A; Csernok E; Reinhold-Keller E; Gross WL
    Adv Exp Med Biol; 1993; 336():487-9. PubMed ID: 8296662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of systemic vasculitis with pooled intravenous immunoglobulin.
    Jayne DR; Davies MJ; Fox CJ; Black CM; Lockwood CM
    Lancet; 1991 May; 337(8750):1137-9. PubMed ID: 1674023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis.
    Ito-Ihara T; Ono T; Nogaki F; Suyama K; Tanaka M; Yonemoto S; Fukatsu A; Kita T; Suzuki K; Muso E
    Nephron Clin Pract; 2006; 102(1):c35-42. PubMed ID: 16174989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin.
    Jordan SC; Toyoda M
    Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):31-8. PubMed ID: 8033432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose pooled immunoglobulin in the therapy of systemic vasculitis.
    Jayne DR; Lockwood CM
    Trans Assoc Am Physicians; 1991; 104():304-12. PubMed ID: 1845155
    [No Abstract]   [Full Text] [Related]  

  • 12. Relationship between disease activity and ANCA level by ELISA in the long-term management of vasculitis.
    De'Oliviera J; Gaskin G; Dash A; Rees AJ; Pusey CD
    Adv Exp Med Biol; 1993; 336():303-4. PubMed ID: 8296622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin.
    Levy Y; Sherer Y; George J; Langevitz P; Ahmed A; Bar-Dayan Y; Fabbrizzi F; Terryberry J; Peter J; Shoenfeld Y
    Int Arch Allergy Immunol; 1999 Jul; 119(3):231-8. PubMed ID: 10436395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ANCA and predicting relapse in systemic vasculitis.
    Jayne DR; Gaskin G; Pusey CD; Lockwood CM
    QJM; 1995 Feb; 88(2):127-33. PubMed ID: 7704563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous immunoglobulin therapy in vasculitis: speculation or evidence?
    Aries PM; Hellmich B; Gross WL
    Clin Rev Allergy Immunol; 2005 Dec; 29(3):237-45. PubMed ID: 16391399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-1-antitrypsin, CRP and interleukin-6 in ANCA-positive vasculitis.
    Grönhagen-Riska C; Teppo AM; Honkanen E; Ikäheimo R
    Adv Exp Med Biol; 1993; 336():337-40. PubMed ID: 8296630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary systemic vasculitis.
    Day C; Savage C
    Minerva Med; 2001 Oct; 92(5):349-63. PubMed ID: 11675579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ANCA-associated vasculitis: diagnostic and therapeutic strategy.
    Ozaki S
    Allergol Int; 2007 Jun; 56(2):87-96. PubMed ID: 17460438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab.
    Eriksson P
    J Intern Med; 2005 Jun; 257(6):540-8. PubMed ID: 15910558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic vasculitis treatment and monitoring update, 2008.
    Yazici Y
    Bull NYU Hosp Jt Dis; 2008; 66(3):228-30. PubMed ID: 18937637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.